CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
15.1 CAD
+0.1 (+0.67%)
CPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making CPH a very profitable company, without any liquidiy or solvency issues. CPH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, CPH could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
CPH had a positive operating cash flow in the past year.
CPH had positive earnings in each of the past 5 years.
CPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CPH's Return On Assets of 11.77% is amongst the best of the industry. CPH outperforms 93.75% of its industry peers.
With an excellent Return On Equity value of 15.23%, CPH belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
CPH has a better Return On Invested Capital (7.23%) than 90.63% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
CPH's Profit Margin of 34.68% is amongst the best of the industry. CPH outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
The Operating Margin of CPH (25.51%) is better than 87.50% of its industry peers.
In the last couple of years the Operating Margin of CPH has declined.
The Gross Margin of CPH (74.32%) is better than 93.75% of its industry peers.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CPH is creating some value.
The number of shares outstanding for CPH has been increased compared to 1 year ago.
The number of shares outstanding for CPH has been reduced compared to 5 years ago.
The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.52 indicates that CPH is not in any danger for bankruptcy at the moment.
CPH's Altman-Z score of 6.52 is amongst the best of the industry. CPH outperforms 93.75% of its industry peers.
CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
The Debt to FCF ratio of CPH (0.45) is better than 93.75% of its industry peers.
CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
CPH has a better Debt to Equity ratio (0.12) than 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.52 |
ROIC/WACC0.87
WACC8.35%
2.3 Liquidity
A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.30, CPH is doing worse than 65.63% of the companies in the same industry.
A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
CPH has a Quick ratio of 0.98. This is in the lower half of the industry: CPH underperforms 62.50% of its industry peers.
CPH does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.17%.
The Revenue has been growing by 8.25% on average over the past years. This is quite good.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
Based on estimates for the next years, CPH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.66% on average per year.
The Revenue is expected to grow by 27.91% on average over the next years. This is a very strong growth
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.78, the valuation of CPH can be described as correct.
81.25% of the companies in the same industry are more expensive than CPH, based on the Price/Earnings ratio.
CPH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.57.
The Price/Forward Earnings ratio is 17.77, which indicates a rather expensive current valuation of CPH.
Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than 75.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.04. CPH is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.78 | ||
| Fwd PE | 17.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH is on the same level as its industry peers.
CPH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CPH is cheaper than 78.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.36 | ||
| EV/EBITDA | 14.46 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPH may justify a higher PE ratio.
A more expensive valuation may be justified as CPH's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)0.33
PEG (5Y)1.29
EPS Next 2Y16.2%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (12/24/2025, 7:00:00 PM)
15.1
+0.1 (+0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.31%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap383.09M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts77.5
Price Target18.39 (21.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0.7%
PT rev (3m)2.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)9.52%
EPS NY rev (3m)-24.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.28%
Revenue NY rev (1m)-2.98%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.78 | ||
| Fwd PE | 17.77 | ||
| P/S | 5.59 | ||
| P/FCF | 9.36 | ||
| P/OCF | 9.33 | ||
| P/B | 2.46 | ||
| P/tB | 12.26 | ||
| EV/EBITDA | 14.46 |
EPS(TTM)0.9
EY5.96%
EPS(NY)0.85
Fwd EY5.63%
FCF(TTM)1.61
FCFY10.68%
OCF(TTM)1.62
OCFY10.71%
SpS2.7
BVpS6.14
TBVpS1.23
PEG (NY)0.33
PEG (5Y)1.29
Graham Number11.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.52 |
F-Score7
WACC8.35%
ROIC/WACC0.87
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year145.61%
EBIT Next 3Y50.92%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you provide the ChartMill fundamental rating for CIPHER PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
How profitable is CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.